clinical trial · NCT05316116
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
H. Lee Moffitt Cancer Center and Research Institute·early phase1·terminated·n = 6
Large Granular Lymphocyte LeukemiaSiltuximab
brief summary
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
started
Feb 15, 2023
primary completion
Oct 18, 2024
completion
Oct 18, 2024
last updated
Feb 5, 2026
official title
A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol